The drugmaker said Monday that the FDA had approved Imfinzi, its PD-L1 inhibitor, for first-line extensive-stage small cell lung cancer, with platinum chemotherapy. The drug creates a new competitive threat to Roche's Tecentriq, which is approved for the same disease setting.
The company said the Phase III CASPIAN study of Imfinzi in first-line, extensive-stage small-cell lung cancer was successful, but did not disclose further details. Roche's Tecentriq is already approved for that indication, which accounts for two-thirds of SCLC cases.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.